Quality of life measurement in bone marrow transplantation: Development of the functional assessment of cancer therapy-bone marrow transplant (FACT-BMT) scale

Bone Marrow Transplantation

Volumn 19, Issue 4, 1997, Pages 357-368

  McQuellon, R P ^a   Russell, G B ^a   Cella, D F ^b   Craven, B L ^a   Brady, M ^b   Bonomi, A ^b   Hurd, D D ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Functional assessment; Marrow transplantation; Quality of life

Indexed keywords

ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER THERAPY; CLINICAL TRIAL; FEMALE; FUNCTIONAL ASSESSMENT; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; RATING SCALE; TIME; VALIDATION PROCESS;

EID: 0031044935     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700672     Document Type: Article

References (36)

1. Deeg HJ. Delayed complications and long-term effects after bone marrow transplantation. Hematol Oncol Clin North Am 1990; 4: 641-657.
2. Hurd DD. Bone marrow transplantation for cancer: an overview. Rec Res Cancer Res 1993; 132: 1-14.
3. Andrykowski MA, Henslee PJ, Farrall MG. Physical and psychosocial functioning of adult survivors of allogeneic bone marrow transplantation. Bone Marrow Transplant 1989; 4: 75-81.
4. Andrykowski MA. Psychosocial factors in bone marrow transplantation: a review and recommendations for research. Bone Marrow Transplant 1994; 13: 357-375.
5. Andrykowski MA, Altmaier EM, Barnett RL et al. The quality of life in adult survivors of allogeneic bone marrow transplantation. Correlates and comparison with matched renal transplant recipients. Transplantation 1990; 50: 399-406.
6. McQuellon RP, Craven B, Russell GB et al. Quality of life in breast cancer patients before and after autologous bone marrow transplantation. Bone Marrow Transplant 1996; 18: 579-584.
7. Andrykowski MA, Greiner CB, Altmaier EM et al. Quality of life following bone marrow transplantation: findings from a multicentre study. Br J Cancer 1995; 71: 1322-1329.
8. Andrykowski MA, Bruehl S, Brady MJ, Henslee-Downey PJ. Physical and psychosocial status of adults one-year after bone marrow transplantation: a prospective study. Bone Marrow Transplant 1995; 15: 837-844.
9. Andrykowski MA, Brady MJ, Greiner CB et al. 'Returning to normal' following bone marrow transplantation: outcomes, expectations and informed consent. Bone Marrow Transplant 1995; 15: 573-581.
10. Grant M, Ferrell B, Schmidt GM et al. Measurement of quality of life in bone marrow transplantation survivors. Qual Life Res 1992; 1: 375-384.
11. Johnson JR, Temple R. Food and Drug Administration requirements for approval of new anticancer drugs. Cancer Treat Rep 1985; 69: 1155-1159.
12. Beitz J, Gnecco C, Justice R. Quality of life endpoints in cancer clinical trials: the US Food and Drug Administration perspective. Monogr Natl Cancer Inst 1996; 20: 7-9.
13. Cella DF, Tulsky DS, Gray G et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11: 570-579.
14. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
15. Sprangers MA, Cull A, Bjordal K et al. The European Organization for Research and Treatment of Cancer. Approach to quality of life assessment: guidelines for developing questionnaire modules. EORTC Study Group on Quality of Life. Qual Life Res 1993; 2: 287-295.
16. Meyerowitz BE. Quality of life in breat cancer patients: the contribution of data to the care of patients. Eur J Cancer 1993; 29A (Suppl. 1): S59-S62.
17. Cella DF, Tulsky DS. Quality of life in cancer: definition, purpose, and method of measurement. Cancer Inv 1993: 11: 327-336.
18. McQuellon RP, Muss HB. Hoffman SL et al. Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer. J Clin Oncol 1995: 13: 858-868.
19. Kassirer JP. Incorporating patients' preferences into medical decisions. New Engl J Med 1994; 330: 1895-1896.
20. Yellen SB, Cella DF. Someone to live for: social well-being, parenthood status, and decision-making in oncology. J Clin Oncol 1995; 13: 1255-1264.
21. Yellen SB, Cella DF, Leslie WT. Age and clinical decision making in oncology patients. J Null Cancer Inst 1994; 86: 1766-1770.
22. Andrykowski MA, Brady MJ, Henslee-Downey PJ. Psychosocial factors predictive of survival after allogeneic bone marrow transplantation for leukemia. Psychosom Med 1994; 56: 432-439.
23. Colon EA, Callies AL, Popkin MK, McGlave PB. Depressed mood and other variables related to bone marrow transplantation survival in acute leukemia. Psychosomatics 1991; 32: 420-425.
24. McCabe MS. A co-operative group report on quality of life research: lessons learned. Monogr Natl Cancer Inst 1996; 20: 63-65.
25. Cella DF, Bonomi AE, Lloyd SR et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 1995; 12: 199-200.
26. Weitzner MA, Meyers CA, Gelke CK et al. The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 1995; 75: 1151-1161.
27. Zubrod CG, Schneiderman M, Frei E et al. Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene hiophosphoramide. J Chron Dis 1960; 11: 7-33.
28. Cella DF, Jacobsen PB, Orav EJ et al. A brief POMS measure of distress for cancer patients. J Chron Dis 1987; 40: 939-942.
29. Burnam MA, Wells KB, Leake B, Landsverk J. Development of a brief screening instrument for detecting depressive disorders. Med Care 1988; 26: 775-789.
30. Sherbourne CD, Steuart AL. The MOS social support survey. Soc Sci Med 1991; 32: 705-714.
31. Cella DF. Manual for the Functional Assessment of Cancer Therapy (FACT) Measurement System (version 3). Rush Cancer Center: Chicago, 1994.
32. Helmstadter GC. Principles of psychological measurement. Appleton Century-Crofts: New York, 1964.
33. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life questionnaire. J Clin Epidemiol 1994; 47: 81-87.
34. Jacobson NS, Traux P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 1991; 59: 12-19.
35. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Controlled Clin Trials 1989; 10: 407-415.
36. Zittoun R, Suciu S, Solbu G et al. Comparison of quality of life (QOL) of patients with acute myelogenous leukemias (AML) in long-term first transplantation (BMT) - allogeneic or autologous - or intensive chemotherapy consolidation (ICC): EORTC-Gimema AML 8A study. Blood 1995; 86 (Suppl. 1): 1718.